- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Sinemet Cr ( Carbidopa / Levodopa )
Sinemet CR (carbidopa/levodopa) is a controlled‑release combination of an aromatic amino acid decarboxylase inhibitor and the metabolic precursor of dopamine. It is indicated for the treatment of the symptoms of idiopathic Parkinson's disease, post‑encephalitic parkinsonism, and symptomatic parkinsonism that may follow injury to the nervous system by carbon monoxide or manganese intoxication. Levodopa is converted to dopamine in the brain, replenishing depleted striatal dopamine, while carbidopa inhibits peripheral decarboxylation of levodopa, allowing more levodopa to reach the central nervous system and reducing peripheral side effects such as nausea. The controlled‑release formulation provides slower and more sustained levodopa plasma concentrations, which may reduce motor fluctuations in some patients.
Usual adult dose: For patients not currently receiving levodopa, the recommended starting dose is one Sinemet CR 25/100 mg tablet twice daily, with doses taken at intervals of at least 6 hours. The dose may be increased gradually by 1 tablet every 1 to 2 days, or at longer intervals, until an optimal response is achieved. Usual maintenance dosing ranges from 2 to 8 tablets per day (total daily levodopa 200 mg to 800 mg) in divided doses, with the 25/100 mg strength allowing fine titration. Doses should be swallowed whole and must not be crushed or chewed. Sinemet CR is not recommended for patients who require a rapid onset of effect, and it should not be used for the acute relief of parkinsonian symptoms. Conversion from immediate‑release carbidopa/levodopa to Sinemet CR requires careful recalculation by the prescriber. If a dose is missed, the patient should take it as soon as remembered, but two doses should not be taken too close together. Abrupt withdrawal or rapid dose reduction may cause a neuroleptic malignant‑like syndrome and must be avoided.
Dosage form: Controlled‑release (extended‑release) tablets: 25 mg carbidopa and 100 mg levodopa per tablet. The tablets are oval, biconvex, and available in distinctive colours; the 25/100 mg strength is usually tan or peach‑coloured, imprinted with the product code. Available in bottles of 100 tablets.
Onset of action: The onset of clinical effect is slower than with immediate‑release formulations because of the controlled‑release matrix. A single dose may begin to relieve parkinsonian symptoms within 30 to 60 minutes in some patients, but the full benefit of dose titration may not be apparent for several days to weeks. Steady motor improvement typically develops after 1 to 2 weeks of dose adjustment.
Duration of action: The controlled‑release formulation provides a more sustained levodopa plasma concentration, with the effect of each dose generally lasting 4 to 6 hours, and in some patients up to 8 hours. This permits less frequent dosing and may reduce end‑of‑dose wearing‑off phenomena compared with immediate‑release levodopa. The elimination half‑life of levodopa in the presence of carbidopa is approximately 1.5 hours, but the clinical effect is prolonged by the formulation.
Alcohol recommendation: Alcohol should be used with caution during treatment with Sinemet CR. Alcohol may increase the central nervous system depressant effects of levodopa, worsening drowsiness, dizziness, and orthostatic hypotension. It can also interfere with the absorption and metabolism of levodopa. Patients should avoid excessive alcohol intake and observe how they respond before driving or performing hazardous tasks.
Most common side effects: Dyskinesias (involuntary movements), nausea, dizziness, orthostatic hypotension, confusion, hallucinations, insomnia, and dry mouth. Nausea may be reduced by taking the dose with food, although a high‑protein meal can compete with levodopa transport and reduce its effect. Dyskinesias and mental changes are dose‑related and may require dose reduction. Orthostatic hypotension can occur at any time; patients should be advised to rise slowly from sitting or lying positions. Hallucinations and psychotic‑like behaviour are more common in elderly patients and those with pre‑existing cognitive impairment; if they occur, the dose may need to be reduced or the drug discontinued under supervision. In rare cases, severe depression or suicidal ideation may emerge. Neuroleptic malignant syndrome with hyperpyrexia and muscle rigidity has been reported after sudden dose reduction or discontinuation. Patients should be monitored for signs of compulsive behaviours, including pathological gambling, hypersexuality, and binge eating, which have been associated with dopaminergic therapy. Sinemet CR is not a rescue medication for acute parkinsonian crisis and must be titrated only by a healthcare professional experienced in movement disorders.
Would you like to try Sinemet CR (Carbidopa / Levodopa) without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
